Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Pain 4Neoplasms 3Chronic Pain 1Cancer Pain 1Agnosia 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Tapentadol × Clear all
NCT00472303 2019-11-04

A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine

Grünenthal GmbH

Phase 3 Completed
622 enrolled 31 charts

Cancer Pain, Neoplasms, Pain

NCT01264887 2019-11-04

Tapentadol in Chronic Malignant Tumour Related Pain

Grünenthal GmbH

Phase 3 Terminated
31 enrolled 19 charts

Agnosia, Neoplasms, Pain, Chronic Pain

NCT00505414 2019-11-01

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

Grünenthal GmbH

Phase 3 Terminated
136 enrolled 9 charts

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡